The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fontana, A.
Right arrow Articles by Zinkernagel, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fontana, A.
Right arrow Articles by Zinkernagel, R. M.

The Journal of Immunology, Vol 143, Issue 10 3230-3234, Copyright © 1989 by American Association of Immunologists

ARTICLES

Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice

A Fontana, K Frei, S Bodmer, E Hofer, MH Schreier, MA Palladino Jr and RM Zinkernagel
Section of Clinical Immunology, University Hospital, Zurich, Switzerland.

The immunoregulatory effects of human recombinant transforming growth factor (rTGF) beta 1 and human recombinant glioblastoma-derived T cell suppressor factor (rG-TsF)/TGF beta 2 was investigated in mice infected with lymphocytic choriomeningitis virus (LCMV) or vaccinia virus. Starting on the day of infection, i.p. injections of 1 microgram/day or rTGF-beta 1 or rG-TsF/TGF-beta 2 suppressed the generation of virus specific CTL. The effect of TGF-beta on CTL (day 8) was less pronounced when TGF-beta treatment was delayed for 3 days after LCMV infection. rG- TsF/TGF-beta 2 also has an inhibiting effect on CTL-mediated disease in LCMV-infected mice: it prolonged the survival time of mice infected with LCMV and reduced the local swelling reaction after infection into the footpad. These results indicate that rTGF-beta 1 and rG-TsF/TGF- beta 2 influence T cell immune reactivity in vivo.


This article has been cited by other articles:


Home page
 JCOHome page
J. J. Nemunaitis
Are Vaccines Making a Comeback in Non-Small-Cell Lung Cancer?
J. Clin. Oncol., March 20, 2008; 26(9): 1402 - 1403.
[Full Text] [PDF]

Home page
 JCOHome page
J. Nemunaitis, R. O. Dillman, P. O. Schwarzenberger, N. Senzer, C. Cunningham, J. Cutler, A. Tong, P. Kumar, B. Pappen, C. Hamilton, et al.
Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 10, 2006; 24(29): 4721 - 4730.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
E. L. Oleszak, J. R. Chang, H. Friedman, C. D. Katsetos, and C. D. Platsoucas
Theiler's Virus Infection: a Model for Multiple Sclerosis
Clin. Microbiol. Rev., January 1, 2004; 17(1): 174 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Q. Phan, J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
PNAS, July 8, 2003; 100(14): 8372 - 8377.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. Maggard, L. Meng, B. Ke, R. Allen, L. Devgan, BS, and D. K. Imagawa
Antisense TGF-{beta}2 Immunotherapy for Hepatocellular Carcinoma: Treatment in a Rat Tumor Model
Ann. Surg. Oncol., January 1, 2001; 8(1): 32 - 37.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
R. E. Rojas, K. N. Balaji, A. Subramanian, and W. H. Boom
Regulation of Human CD4+ alpha beta T-Cell-Receptor-Positive (TCR+) and gamma delta TCR+ T-Cell Responses to Mycobacterium tuberculosis by Interleukin-10 and Transforming Growth Factor beta
Infect. Immun., December 1, 1999; 67(12): 6461 - 6472.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. W. v. Ginkel, S. M. Wahl, J. F. Kearney, M.-N. Kweon, K. Fujihashi, P. D. Burrows, H. Kiyono, and J. R. McGhee
Partial IgA-Deficiency with Increased Th2-Type Cytokines in TGF-{beta}1 Knockout Mice
J. Immunol., August 15, 1999; 163(4): 1951 - 1957.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. Yano, B. N. Mora, J. M. Ritter, R. K. Scheule, N. S. Yew, T. Mohanakumar, and G. A. Patterson
EX VIVO TRANSFECTION OF TRANSFORMING GROWTH FACTOR-{beta}1 GENE TO PULMONARY ARTERY SEGMENTS IN LUNG GRAFTS
J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 705 - 713.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
L. Genestier, S. Kasibhatla, T. Brunner, and D. R. Green
Transforming Growth Factor beta 1 Inhibits Fas Ligand Expression and Subsequent Activation-induced Cell Death in T Cells via Downregulation of c-Myc
J. Exp. Med., January 18, 1999; 189(2): 231 - 239.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Erard, J. A. Garcia-Sanz, R. Moriggl, and M.-T. Wild
Presence or Absence of TGF-{beta} Determines IL-4-Induced Generation of Type 1 or Type 2 CD8 T Cell Subsets
J. Immunol., January 1, 1999; 162(1): 209 - 214.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. D. Gorham, M. L. Guler, D. Fenoglio, U. Gubler, and K. M. Murphy
Low Dose TGF-{beta} Attenuates IL-12 Responsiveness in Murine Th Cells
J. Immunol., August 15, 1998; 161(4): 1664 - 1670.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. J. Bright and S. Sriram
TGF-{beta} Inhibits IL-12-Induced Activation of Jak-STAT Pathway in T Lymphocytes
J. Immunol., August 15, 1998; 161(4): 1772 - 1777.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1989 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1989 by The American Association of Immunologists, Inc. All rights reserved.